文献速递临床试验与 GCP

普伐他汀预防妊娠期高血压疾病复发:一项随机、开放标签、平行分组、三臂试验的研究方案

Pravastatin for the prevention of recurrent hypertensive disorders of pregnancy: study protocol for a randomized, open-label, parallel-group, three-arm trial.
PubMed 文献 · Trials · 2025-11-12

本研究为在日本四个招募中心开展的随机、开放标签、平行分组、三臂试验,纳入有妊娠期高血压疾病史且高危的孕妇,所有组均以阿司匹林为基础治疗,比较口服普伐他汀5 mg每日一次联合拜阿司匹林100 mg每日一次、口服普伐他汀10 mg每日一次联合拜阿司匹林100 mg每日一次与单用拜阿司匹林100 mg每日一次的疗效,主要结局为妊娠期高血压发生率。

要点

  • 三臂试验均以拜阿司匹林100 mg每日一次为基础治疗,比较普伐他汀5 mg、10 mg联合阿司匹林与单用阿司匹林。
  • 主要结局为妊娠期高血压发生率,次要结局包括子痫前期、 gestational hypertension、sFlt-1/PlGF比值等。
  • 研究在日本四个招募中心开展,纳入有妊娠期高血压疾病史且高危的孕妇。

核心结论

  • 本试验旨在评估早期普伐他汀治疗是否能有效预防妊娠期高血压疾病。
  • 研究结果预期对母婴长期健康及卫生经济学具有广泛意义。

研究设计与样本

  • 随机、开放标签、平行分组、三臂试验,所有组均以阿司匹林为基础治疗。
  • 从日本四个招募中心招募有妊娠期高血压疾病史且处于高风险的孕妇。
  • 三种干预分别为口服普伐他汀5 mg每日一次联合口服拜阿司匹林100 mg每日一次、口服普伐他汀10 mg每日一次联合口服拜阿司匹林100 mg每日一次、单用口服拜阿司匹林100 mg每日一次。

关键数值与推荐

  • 主要结局指标为妊娠期高血压的发生率。
  • 次要结局指标包括子痫前期和妊娠期高血压的发生率、母体血清可溶性fms样酪氨酸激酶-1/胎盘生长因子比值以及可溶性fms样酪氨酸激酶-1和胎盘生长因子水平、母亲是否蛋白尿、胎盘重量、脐带血脂谱、妊娠期高血压疾病相关并发症(胎盘早剥、溶血、肝酶升高和低血小板计数综合征及子痫)的发生率、诊断妊娠期高血压疾病的孕周、重度妊娠期高血压疾病的发生率以及新生儿结局(出生体重、小于胎龄儿百分比、新生儿重症监护病房入住率和听性脑干反应)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hypertensive disorders of pregnancy lead to a critically ill maternal/fetal state due to maternal organ failure and fetal dysfunction related to placental abruption or impaired placental circulation. No treatment with established efficacy for hypertensive disorders of pregnancy is currently available, and delivery is the only definitive treatment. This article describes the study protocol for a trial that aims to evaluate whether early pravastatin treatment is effective in preventing hypertensive disorders of pregnancy. METHODS: A randomized, open-label, parallel-group, three-arm trial will be conducted with aspirin administered as the baseline treatment across all groups. Pregnant women with a history of hypertensive disorders of pregnancy who are at high risk of developing hypertensive disorders of pregnancy will be recruited from four recruitment sites in Japan. The three interventions of the study comprise oral pravastatin 5 mg once daily with oral bayaspirin 100 mg once daily, oral pravastatin 10 mg once daily with oral bayaspirin 100 mg once daily, and oral bayaspirin 100 mg once daily alone. The primary outcome measure is the incidence of hypertension during pregnancy. The secondary outcome measures include incidence rates of preeclampsia and gestational hypertension, maternal serum soluble fms-like tyrosine kinase-1/placental growth factor ratio, as well as soluble fms-like tyrosine kinase-1 and placental growth factor levels, whether the mother is proteinuric, placental weight, umbilical cord blood lipid profile, the incidence of hypertensive disorders of pregnancy-related complications (placental abruption, hemolysis, elevated liver enzymes, and low platelet count syndrome, and eclampsia), week at diagnosis of hypertensive disorders of pregnancy, incidence of severe hypertensive disorders of pregnancy, and neonatal outcomes (birth weight, percentage of small for gestational age neonates, neonatal intensive care unit admission rate, and auditory brainstem response). DISCUSSION: The results of this study are expected to have wide-ranging implications given the effects of hypertensive disorders of pregnancy on long-term maternal and child health, as well as health economics. TRIAL REGISTRATION: Japan Registry of Clinical Trials (Trial ID: jRCTs031230067; registered May 11, 2023; https://jrct.mhlw.go.jp/en-latest-detail/jRCTs031230067 ).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Kumasawa K, Kashiwabara K, Inoue M, et al. Pravastatin for the prevention of recurrent hypertensive disorders of pregnancy: study protocol for a randomized, open-label, parallel-group, three-arm trial. Trials. 2025. PMID: 41225548. doi:10.1186/s13063-025-09136-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。